CryoGen Inc. Announces Two-Year Follow Up Results.Business Editors & Health/Medical Writers SAN DIEGO--(BW HealthWire)--April 15, 2002 Charles Tribie', president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CryoGen cry·o·gen n. A liquid, such as liquid nitrogen, that boils at a temperature below about 110 Kelvin (-160°C) and is used to obtain very low temperatures; a refrigerant. Inc., announced today the results of the company's two-year follow-up of patients treated in its initial FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clinical trial. That trial led to the April 2001 PMA PMA (papillary-marginal-attached), n a system of epidemiologic scoring of periodontal disease devised by Schour and Massler in which the symbols denote the areas involved in gingival inflammation. PMA Progressive muscular atrophy approval of the company's Her Option System for endometrial ablation. "The results at two years showed excellent outcomes overall with a continuing trend of improvement," stated Charles Tribie' CEO. At two years after treatment with Her Option Therapy, 94 percent of the patients surveyed achieved a decrease to normal bleeding levels or less. Ninety-six percent of patients were satisfied with treatment with 97 percent saying they would recommend Her Option Therapy to a friend. Eighty percent of patients had mild to no symptoms of pain and cramping associated with menstruation. "The two year data showing a 94 percent success rate, along with Her Option's clear advantages over other methods used for treatment, continues to drive rapid acceptance of the system throughout the U.S.," noted Will Rutan, executive V.P. sales and marketing. "I have performed over 300 procedures using Cryogen's Her Option Cryoblation system," added Dr. Seth Herbst, an OB/GYN based in West Palm Beach, Fla., "My patients are thrilled with the comfort and outcome of the treatment. They also love the option of being treated in my office with just a local anesthetic local anesthetic n. An agent that, when applied directly to mucous membranes or when injected about the nerves, produces loss of sensation by inhibiting nerve excitation or conduction. . There is no question that Her Option is the best treatment alternative for excessive bleeding." The Her Option Cryoblation System is the only FDA approved cryogenic device for treatment of excessive menstrual bleeding. Cryogenics cryogenics: see low-temperature physics. cryogenics Study and use of low-temperature phenomena. The cryogenic temperature range is from −238°F (−150°C) to absolute zero. At low temperatures, matter has unusual properties. , the application of extreme cold temperatures, has been used for over 25 years to successfully treat a variety of women's health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. issues. About CryoGen Inc. CryoGen Inc. is an emerging growth medical device company focused on the development and marketing of its patented Her Option(TM) cryoablation technology. CryoGen has received FDA approval for its minimally invasive, closed cycle cryoablation device and supporting system that enables physicians to ablate ab·late v. To remove or destroy the function of. ablate to remove, especially by cutting. ablate verb To remove; excise (destroy) tissue at extremely low temperatures. The company is headquartered in San Diego, and backed by Kleiner Perkins Caufield and Byers, INVESCO, JHK Investments and other top tier venture investors. Patient and physician information can be accessed at www.heroption.com or www.cryogen-inc.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion